Clinical Trial Update: Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating safety and efficacy of pegvisomant in children with growth hormone excess has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Excess
• Pituitary Disease
• Pituitary Gigantism

Drugs mentioned

• Pegvisomant (pegvisomant)

Snippet

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Conditions: Pituitary Disease | Phase 3 | Status: COMPLETED